AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03184480
Drug: Arnuity Ellipta
RxNorm normalized name: Arnuity Ellipta
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The active component of Arnuity Ellipta is fluticasone furoate and it is indicated for the treatment of bronchial asthma. Post-marketing investigation of ARNUITY ELLIPTA will be carried out in this analysis.
Trial: NCT02261779
Drug: Tranylcypromine
RxNorm normalized name: Tranylcypromine
DrugBank: Tranylcypromine (DB00752)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00990054
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 240 mcg/kg/dose and proceeding to escalating dose levels for determination of the single-dose maximum tolerated dose (MTD) provided that there are no unacceptable dose limiting toxicities
Trial: NCT00356889
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally, 150 mg, once daily.
Trial: NCT00163462
Drug: Ciclesonide
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02107092
Drug: Sodium Zirconium Cyclosilicate
RxNorm normalized name: sodium zirconium cyclosilicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral 10g once daily with breakfast for 11 months.
Trial: NCT01386294
Drug: Tenofovir gel
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir gel is a clear, transparent, viscous gel at concentrations of 1% formulated in purified water with edentate disodium, citric acid, glycerin, methylparaben, propylparaben, HEC, and pH adjusted to 4-5. Tenofovir gel will be supplies in a 4 ml single use applicator containing approximately 4 grams of gel, equivalent to approximately 40mg of tenofovir.
Trial: NCT01587339
Drug: retigabine/ezogabine
DrugBank: Ezogabine (DB04953)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral - all doses
Trial: NCT01587339
Drug: lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral - all doses
Trial: NCT01587339
Drug: zonisamide
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral - all doses
Trial: NCT01587339
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral - all doses
Trial: NCT01587339
Drug: eslicarbazepine
RxNorm normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral - all doses
Trial: NCT01638078
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide, pill, 50 mg, once p.d., 6 weeks
Trial: NCT01466530
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sublingual misoprostol was given by putting two moistened tablets of misoprostol (400 µg) under the tongue and allowing them to dissolve (Misotac®, Sigma Pharmaceutical Industries, Egypt) (200 µg/tablet).
Trial: NCT02581748
Drug: HLX02
RxNorm normalized name: Trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02581748
Drug: Herceptin
RxNorm normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00537030
Drug: Asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IM
Trial: NCT00517322
Drug: ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ramipril 2.5- 5 mg once daily
Trial: NCT00517322
Drug: irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: irbesartan 150-300 mg once daily
Trial: NCT00419146
Drug: Ethyl-eicosapentaenoic acid (EPA)
RxNorm normalized name: Ethyl eicosapentaenoate
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, 2 g per day for 16 weeks
Trial: NCT00419146
Drug: Vitamins E + C
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RRR-alpha-tocopherol 392 mg + slow-release ascorbic acid 1000 mg per day, for 16 weeks
Trial: NCT00414765
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00148772
Drug: Erlotinib (Tarceva)
RxNorm normalized name: erlotinib Oral Tablet [Tarceva]
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00053924
Drug: perifosine
RxNorm normalized name: Perifosine
DrugBank: Perifosine (DB06641)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01543828
Drug: indacaterol
RxNorm normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: delivered via single-dose dry-powder inhaler
Trial: NCT01925898
Drug: Midazolam - active comparator
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam - 0.7mg/kg single dose
Trial: NCT01925898
Drug: Experimental Arm: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Ketamine 5mg/kg Single dose
Trial: NCT00073528
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1500 mg orally once a day
Trial: NCT00073528
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg orally once a day
Trial: NCT00193141
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00193141
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00193141
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04625114
Drug: Camostat
RxNorm normalized name: camostat
DrugBank: Camostat (DB13729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D1-\>D5);
Trial: NCT04625114
Drug: Camostat
RxNorm normalized name: camostat
DrugBank: Camostat (DB13729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D6-\>D10);
Trial: NCT01866449
Drug: Cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01733966
Drug: Secnidazole, ciprofloxacine
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2g of microgranules of secnidazole. a single dose per day during 3 days.~1g of Ciprofloxacin (2 tablets of 500mg per day during 3 days)
Trial: NCT01733966
Drug: Amoxicillin-Clavulanic Acid
RxNorm normalized name: amoxicillin / clavulanate
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3g of Amoxicillin-Clavulanic acid (3 powder packet of 1g per day during 10 days)
Trial: NCT01023867
Drug: donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: from 5mg to 10mg, once a day, 12 months
Trial: NCT00535275
Drug: Chemotherapy without Cisplatine
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m² D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
Trial: NCT02096510
Drug: Solu-Cortef
RxNorm normalized name: Solu-Cortef
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration by pump for minimum 2 weeks
Trial: NCT02096510
Drug: Cortef
RxNorm normalized name: Cortef
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: tablet treatment 2 ro 3 times per day for 14 days
Trial: NCT00258271
Drug: cladribine
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00258271
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03295851
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in the intervention group will receive preoperative IV ferric carboxymaltose, given as a single dose (15 mg/kg body weight, to a maximum dose of 1000 mg) over 30 minutes.
Trial: NCT03295851
Drug: Ferrous Fumarate
RxNorm normalized name: Ferrous Fumarate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given oral iron as per current clinical protocol, which is Ferrous fumarate 200mg twice daily.
Trial: NCT02721888
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00258271
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00733954
Drug: clobetasol propionate spray
RxNorm normalized name: clobetasol propionate Topical Spray
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Apply twice daily
Trial: NCT00733954
Drug: clobetasol propionate ointment
RxNorm normalized name: Clobetasol Propionate Ointment
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Apply twice daily
Trial: NCT00225979
Drug: Octreotide LAR
RxNorm normalized name: octreotide LAR 20 MG Injection
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01056172
Drug: Peginterferon alfa-2a and Ribavirin
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. PegIFN alfa-2a (PEgasys) 180 ug/week~2. Weight-based ribavirin (\<65kg: 800mg/day, 65-85kg: 1000mg/day, \>85kg: 1200mg/day)~3. Treatment duration: 16 weeks
Trial: NCT01056172
Drug: Peginterferon alfa-2a and Ribavirin
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. PegIFN alfa-2a (PEgasys) 180 ug/week~2. Weight-based ribavirin (\<65kg: 800mg/day, 65-85kg: 1000mg/day, \>85kg: 1200mg/day)~3. Treatment duration: 24 weeks
Trial: NCT00602095
Drug: misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.025mg tablet vaginally every 4 hour until progress
Trial: NCT04417179
Drug: Bupivacaine 0.25% Injectable Solution
RxNorm normalized name: BUPivacaine 0.25% injectable solution
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local Anesthetic used in both blocks
Trial: NCT00962442
Drug: N-Acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg/kg for 14 days, intravenously
Trial: NCT00681174
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg i.v. bolus, 30 minutes before the expected end of anesthesia
Trial: NCT00681174
Drug: oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg p.o. 1 h before the start of anesthesia
Trial: NCT00681174
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Plasma concentration target-controlled infusion based on bispectral index values~* Acceptable range of concentrations: 2-4 µg/mL~* Target bispectral index values: 40-60~* Infusion starts at 4 µg/ml target, after pre-oxygenation (i.e., start of anesthesia)
Trial: NCT00681174
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g i.v. bolus 30 min before the end of anesthesia; 1 g i.v. bolus q8h thereafter.
Trial: NCT00681174
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous infusion pump (IV-PCA).~* 50 mg morphine in 50 ml saline solution (1 mg/ml)~* Incremental dose: 1 mg~* Lock-out time: 8 min~* Limit: 40 mg in 4 h~* Background infusion: none
Trial: NCT03848754
Drug: Gemtuzumab Ozogamicin 2 mg/m^2
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: GO 2 mg/m\^2 on Day 1 of a 28-day cycle.
Trial: NCT03848754
Drug: Pracinostat - 45 mg
RxNorm normalized name: Pracinostat
DrugBank: Pracinostat (DB05223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction: 45mg administered orally 3 days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by 1 week of rest, in 28-day cycles.
Trial: NCT03848754
Drug: Pracinostat - 60 mg
RxNorm normalized name: Pracinostat
DrugBank: Pracinostat (DB05223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalation: 60 mg administered orally three days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by one week of rest, in 28-day cycles.
Trial: NCT01059110
Drug: Salicylate ointment
RxNorm normalized name: salicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cream, one application every night, for 90 days
Trial: NCT01059110
Drug: Imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: cream, one dose of 250 mg, one application 3 times a week during 12 hours, for 90 days
Trial: NCT00136526
Drug: Docetaxel and Diethylstilbestrol (DES)
RxNorm normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects receive docetaxel 36 Mg/m2weekly for ten cycles (3 weeks out of every 4) and DES 1 mg daily for 40 weeks or until there is evidence of disease progression, whichever occurs first.
Trial: NCT00625495
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg Intravenous infusion over 3 minutes
Trial: NCT00625495
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg Oral
Trial: NCT00873197
Drug: granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sancuso® 3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days (168 hours) followed by a second patch applied to the opposite arm at 168 hours for a further 7 days (168 to 336 hours).~Kytril® (granisetron hydrochloride) 1 mg/mL; IV; 0.01 mg/kg (maximum 1 mg) administered over 30 seconds immediately following patch application on Day 1 only.
Trial: NCT00445484
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given orally
Trial: NCT03951051
Drug: Olmesartan Medoxomil 40 mg
RxNorm normalized name: olmesartan medoxomil 40 MG
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan Medoxomil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each film-coated tablet contains 40 mg of olmesartan medoxomil.
Trial: NCT04305275
Drug: SAGE-324
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAGE-324 oral tablet
Trial: NCT04305275
Drug: SAGE-324 Placebo
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAGE-324 matched placebo oral tablet
Trial: NCT04267770
Drug: Insulin (circadian)
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participant's own insulin adjusted to circadian infusion rates
Trial: NCT04267770
Drug: Insulin (flat rate)
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participant's own insulin set to flat basal rates
Trial: NCT00995475
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00927654
Drug: Iloprost (Ventavis)
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice 20 µg at day 0 (total dose 40 µg) intraoperatively
Trial: NCT00927654
Drug: Isotonic Sodium Chloride solution 0.9 % (placebo)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice at day 0 intraoperatively
Trial: NCT01079988
Drug: Cyclosporins
RxNorm normalized name: Cyclosporine
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose 4.0 - 5.1 mg/kg/day until clinical improvement. Upon clinical improvement, cyclosporin dose to be tapered by 50% every two weeks.
Trial: NCT00243698
Drug: SonoVue (sulphur hexafluoride microbubbles)
DrugBank: Sulfur hexafluoride (DB11104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One contrast enhanced ultrasonography using sonovue / 4.8 ml per injection (maximum of 3 injections)
Trial: NCT01974141
Drug: Dapsone Gel
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
Trial: NCT01974141
Drug: Dapsone Gel Vehicle
RxNorm normalized name: dapsone Topical Gel
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
Trial: NCT03252353
Drug: octreotide capsules
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: octreotide capsules 40 mg/day, 60 mg/day, 80 mg/day (individual dose titration)
Trial: NCT00940381
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Beginning dose 3 mg by mouth on Day 1, and 1 mg on Days 2 - 28 for a 28 day cycle.
Trial: NCT00940381
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Beginning dose 100 mg/m\^2 by vein over two hours on Day 1, and 65 mg/m\^2 on Days 8, 15 and 22 for a 28 day cycle.
Trial: NCT00546299
Drug: oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cylinder and concentrator, dosage to maintain SpO2 above 92%, used during exertion
Trial: NCT02431897
Drug: Conjugated Estrogens Cream
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for \>5 weeks before surgery, then 2x/week for 1 year after surgery.
Trial: NCT03044249
Drug: MP-101
RxNorm normalized name: AMP-101
DrugBank: AMP-101 (DB18253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT00791947
Drug: CHOEP + G-CSF followed by BEAM
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CHOEP:~Cyclophosphamide: 750 mg/m2 i.v. day1 Hydroxydaunorubicin: 50 mg/m2 i.v. day1 Vincristine: 1.4 mg/m2 (max 2 mg) i.v. day 1 Etoposide: 100 mg/m2 i.v. day 1-3 Prednisone: 100 mg daily p.o. day 1-5~BEAM:~Carmustine: 300 mg/m2 i.v. day 1 Etoposide: 100 mg/m2 i.v. x2 daily day 2-5 Cytosine arabinoside: 200 mg/m2 i.v. x2 daily or 400 mg/m2 as continuous 24 hrs i.v. infusion, day 2-5 Melphalan: 140 mg/m2 i.v. day 6
Trial: NCT01607645
Drug: decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01607645
Drug: idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01607645
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02782520
Drug: Ringer Lactate (10ml/kg) fluid expansion
RxNorm normalized name: lactate
DrugBank: L-Phospholactate (DB01733)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00279019
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium will be given orally as overfoiled strips of 5 capsules, each containing 18 micrograms of tiotropium (as bromide monohydrate) administered via a HandiHaler device.
Trial: NCT00887263
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 mg TID
Trial: NCT00857623
Drug: AZD2066
RxNorm normalized name: AZD2066
DrugBank: AZD2066 (DB17078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, once daily, 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28.
Trial: NCT02221349
Drug: Sodium fluoride paste
RxNorm normalized name: sodium fluoride Paste
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Toothpaste used by subject
Trial: NCT03974425
Drug: Aflibercept Injection [Eylea]
RxNorm normalized name: aflibercept Injection [Eylea]
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravitreal injection of Aflibercept in resistant DME.
Trial: NCT02221349
Drug: Stannous fluoride paste
RxNorm normalized name: stannous fluoride Paste
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Toothpaste used by subject